X

Xeris Biopharma Holdings
D

XERS

3.33000
USD
0.03
(0.91%)
مفتوح الان
حجم التداول
10,550
الربح لكل سهم
-0
العائد الربحي
-
P/E
-8
حجم السوق
496,441,265
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALDX
    -0.02000
    (-0.40%)
    5.02000 USD
    A
    AQST
    0.02000
    (0.64%)
    3.15000 USD
    B
    BHC
    0.19500
    (2.52%)
    7.92000 USD
    E
    EPIX
    -0.03500
    (-2.01%)
    1.70500 USD
    E
    ESPR
    -0.08500
    (-3.86%)
    2.11500 USD
    GILD
    GILD
    -0.300
    (-0.32%)
    92.720 USD
    I
    INSM
    0.010
    (0.01%)
    78.460 USD
    MRK
    MRK
    0.400
    (0.42%)
    95.930 USD
    R
    RDHL
    0.09000
    (1.40%)
    6.51000 USD
    S
    SAGE
    -0.04500
    (-0.64%)
    6.98000 USD
    المزيد
الأخبار
المقالات

العنوان: Xeris Biopharma Holdings

القطاع: Healthcare
الصناعة: Biotechnology
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.